Rallis Efstathios, Bournia Vasiliki-Kalliopi, Verros Constantinos, Iliopoulos Alexios
Department of Dermatology, Veterans Administration Hospital (NIMTS), Monis Petraki 10-12, 11521 Athens, Greece.
Department of Rheumatology, Veterans Administration Hospital (NIMTS), Monis Petraki 10-12, 11521 Athens, Greece.
Case Rep Med. 2015;2015:315490. doi: 10.1155/2015/315490. Epub 2015 Mar 1.
The use of tumor necrosis factor-α (TNF-α) inhibitors in the treatment of various inflammatory conditions has altered the field of medical therapeutics. Squamous cell carcinoma is the second most common cancer of the skin, usually affecting sun-exposed areas of the body. We present here the case of a 75-year-old woman with rheumatoid arthritis, who developed an intertoe squamous cell carcinoma (SCC) of the right foot. According to her history, she received etanercept and methotrexate for 5 years for rheumatoid arthritis. The rare localization of this cancer could suggest a possible linkage of the malignancy to the chronic intake of anti-TNF-α treatment. This is the first reported case of an interdigital SCC developed under the use of an anti-TNF-α agent.
肿瘤坏死因子-α(TNF-α)抑制剂在各种炎症性疾病治疗中的应用改变了医学治疗领域。鳞状细胞癌是皮肤第二常见的癌症,通常累及身体暴露于阳光的部位。我们在此报告一例75岁患类风湿关节炎的女性,她右足趾间出现了鳞状细胞癌(SCC)。根据她的病史,她因类风湿关节炎接受依那西普和甲氨蝶呤治疗达5年。这种癌症罕见的发病部位可能提示该恶性肿瘤与长期使用抗TNF-α治疗之间存在潜在联系。这是首例报道的在使用抗TNF-α药物过程中发生的趾间SCC病例。